Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| As a point of reference, we believe this is good news about the potential commercial opportunity for FC2 in the United States contraceptive market |
| We believe these results support our strategy and demonstrate high demand for FC2 |
| This expanded Phase 3 study would help us with more certainty in the timing of patient enrollment and offers a larger market opportunity |
| And that's been our success, so that we don't dilute our shareholders |
| So again we're very excited about this base business |
| We believe this commitment further enhances our financial flexibility and aligns with long-term strategy for a shareholder value creation |
| Having taken the time to refine our marketing, drive operational improvements, and enhance the patient experience during the initial launch phase, there are increasing new prescriptions being written and filled through our FC2 telehealth portal |
| In the two phase two clinical studies conducted in women with angioreceptor positive, HER2-negative metastatic breast cancer, Enobosarm demonstrates significant anti-tombor efficacy in heavily pretreated cohorts that failed estrogen blocking agents, chemotherapy, and the CDK46 inhibitors, and it was well tolerated with a very favorable safety profile |
| public sector, such as State Departments of Health, 501C3 organizations, to generate the strong unit sales growth we have seen in fiscal 2023 from this channel |
| The company has completed a positive phase two and a positive Phase 3 COVID-19 clinical studies that have demonstrated that sabizabulin treatment resulted in significant mortality benefit and hospitalized monitor severe patients with COVID-19 viral lung infections and high risk for ARDS |
| That's, I'm very happy with that because that means we're on that slope going up and we get a good price for that |
| I mean, we're good for the next 12 months, but 2024, a lot of part of 2024, as you move into 2025, I mean, the Portals should be doing a pretty good job at helping, the FC2 portals do a pretty good job of helping us with cash as far as to continue to develop our two main Phase 3 programs |
| FC2 prescription business will demonstrate robust growth, both from our dedicated FC2 telehealth portal and for the addition of new telehealth and other commercial distribution |
| And so if that happens, and again, again, I'm just thinking ahead, Enobosarm by itself is a very well-tolerated medicine |
| As the only FDA approved female internal condom in the United States, FC2 is a well-established and serious business |
| So in summary, the way to think of it is that U.S.-based business is growing and it's palpable and we're seeing it and it feels good prescription business and that's our largest profit margin |
| During the third quarter of fiscal year 2023, we saw our new prescriptions grow over 115%, providing prescriptions to approximately 4,400 patients |
| Our financial position, we have successfully reduced expenses after we received the COVID-19 EUA declination |
| And 4400, and yes, so that's pretty good |
| And so we see 2024 being a better year |
| We're currently supplying a large multi-year South African tender for female condoms, which is expected to continue until 2025, and we have seen sales grow in the current year as the current tender launched |
| We're working to increase net revenues in future periods by growing awareness and driving demand through increased FC2 marketing efforts through our telehealth platform and through discussions with potential new distribution partners in the telehealth sector |
| Companies reported positive preclinical data for Sabizabulin and influenza A induced ARDS and forpox virus |
| For that reason, we have found, I mean, the Internet has been an incredible way |
| Prescription Channel for a growing awareness and driving demand of FC2 through increased marketing efforts for our own telehealth platform and pursuing additional distributors in the telehealth sector |
| So that feels good |
| But we're encouraged |
| So on April 4, 2023, the company announced results from a preclinical study of sabizabulin, demonstrating robust anti-inflammatory activity with improved outcomes in the H1N1 influenza induced pulmonary inflammation mouse ARDS model |
| We plan to continue to grow and deepen our investment in a profitable way by further expanding our presence both in social media channels and online search |
| Patients with viral lung infections who are in oxygen support and who are at risk for ARDS represent a high unmet need and a potentially large market opportunity with very limited treatment options |
| Statement |
|---|
| prescription business net revenues is primarily due to lower volume from telemedicine customers because of ongoing challenges which included changes in strategy, the impact of rebranding, and reduction in marketing spending and thereby resulting in a slowdown in orders during recent quarters and ultimately those customers discontinuing operations |
| The prescription business net revenues decreased from $6.7 million in the prior year third quarter to $863,000 |
| COVID-19 will be a problem for the foreseeable future and there's a need for effective therapies, especially for these hospitalized patients, with moderate to severe COVID-19 infection in highways for ARDS |
| We recorded a provision for credit losses of $3.9 million during the period related to the total receivables due from the pill club because of the uncertainty of their financial condition |
| Net revenues from another prescription channel customer were $11.3 million in the prior year period and zero in the current year period which we understand are due to inventory management after a reduction in orders from its most significant customer which discontinued its operations thereby resulting in our customer ceasing orders |
| The reduction in the prescription business net revenues is due to not having any revenues from the pill club in the current period due to the pill club's Chapter 11 bankruptcy final |
| The operating loss for the period was $70.1 million compared to $38.6 million in the prior year period |
| prescription business which has a higher profit margin comprising a smaller percentage of total net revenues and higher production costs per unit due to lower production volumes |
| The reduction in gross profit and gross margin is driven primarily by the change in the sales mix with our US-FC2 prescription business representing 26% of net revenues in the current period compared to 70% in the prior period |
| The bottom line result for the first nine months of fiscal 2023 was a net loss of $69.3 million or $0.83 per diluted common share compared to a net loss of $42.8 million or $0.53 per diluted common share in the prior period |
| Operating income for the quarter was $4.9 million compared to an operating loss of $21.8 million in the prior year quarter |
| If either of the interim efficacy analyses meet the statistical significance criteria, the trial could be stopped for efficacy |
| The decrease in gross profit in gross margin is due primarily to the change in sales mix with the U.S |
| The bottom line result for the third quarter of fiscal 2023 was net income of $6.3 million or $0.07 per diluted common share compared to a net loss of $22.2 million or $0.28 per diluted common share in the prior year third quarter |
| Operating expenses for the quarter decreased to $13.8 million from the prior year's quarter of $28.9 million |
| The company's cash burn during this quarter was $7.3 million, a $16.1 million reduction compared to the prior quarter |
| As ARDS results from the over-exaggerated immune inflammatory response by patients to the virus infection rather than by direct injury from the virus itself |
| The reduction in the U.S |
| A single outbreak involving any one of these viruses would be an immediate global emergency with limited existing options for treatment |
| So this is what happened |
Please consider a small donation if you think this website provides you with relevant information